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Objectives: Alterations in mitochondrial DNA (mtDNA) copy number have been widely reported in various human
cancers, and been considered to be an important hallmark of cancers. However, little is known about the value of
copy number variations of mtDNA in the prognostic evaluation of laryngeal cancer.
Design and methods: Using real-time quantitative PCR method, we investigated mtDNA copy number in a cohort
of laryngeal cancers (n =204) and normal laryngeal tissues (n =40), and explored the association of variable mtDNA
copy number with clinical outcomes of laryngeal cancer patients.
Results: Our data showed that the relative mean mtDNA content was higher in the laryngeal cancer patients
(11.91 ± 4.35 copies) than the control subjects (4.72 ± 0.70 copies). Moreover, we found that mtDNA content was
negatively associated with cigarette smoking (pack-years), tumor invasion, and TNM stage. Notably, variable mtDNA
content did not affect overall survival of laryngeal cancer patients. However, when the patients were categorized
into early-stage and late-stage tumor groups according to TNM stage, we found that low mtDNA content was
strongly associated with poor survival in the former, but not in the latter.
Conclusions: The present study demonstrated that low mtDNA content was strongly correlated with some of
clinicopathological characteristics, such as cigarette smoking, tumor invasion and TNM stage. In addition, we
found a strong link between low mtDNA content and worse survival of the patients with early-stage tumors. Taken
together, low copy number of mtDNA may be a useful poor prognostic factor for early-stage laryngeal cancer
patients.
Virtual slides: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1841771572115955
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Laryngeal cancer represents the second most common
malignancy of the head and neck worldwide [1]. Given
the fundamental role the larynx plays in human speech
and communication, determining the optimal manage-
ment of laryngeal cancer is critical. Despite multiple and
aggressive therapeutic interventions, there has been no
fundamental improvement in the 5-year survival rates
of the patients over the past decades [1,2]. Current* Correspondence: phou@mail.xjtu.edu.cn
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stated.methods used to predict the outcome of laryngeal cancer
patients include some clinicopathological factors, includ-
ing TNM stage, differentiation grade and metastasis, as
well as several biomarkers, such as hTERC amplification
and VEGF expression [3-11].
In recent years, copy number variations of mitochon-
drial DNA (mtDNA) have been reported in various human
cancers, including head and neck cancer [12,13]. The
major role of mitochondria, which are organelles found
in all nucleated cells, is to generate cellular adenosine
triphosphate (ATP) through oxidative phosphorylation
[14]. Human mitochondrial DNA (mtDNA) is a 16.5-kb
double-stranded DNA molecule, which contains genestd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Table 1 Clinicopathological characteristics of laryngeal
cancer patients
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tRNAs and 2 rRNAs [15]. Mutations in the displacement
loop (D-loop), a noncoding region essential for the replica-
tion and transcription of mtDNA, can cause a reduction
in mtDNA copy number or altered mtDNA gene expres-
sion [16,17]. Cellular mtDNA content typically ranges
from hundreds to more than 10 000 copies per cell, vary-
ing across different cell types. Because of lack of introns,
inability to bind to histones, and inefficient mtDNA proof-
reading and DNA repair systems, mtDNA is more suscep-
tible to oxidative damage than nuclear DNA (nDNA) [18].
In general, mtDNA copy number in the cells is not under
stringent control; and various internal or external factors
associated with ATP demand may influence its level, such
as hypoxia (a strict microenvironment that carcinoma cells
can proliferate fast and survive in). Until now, there have
been only a few studies suggesting an increase in mtDNA
copy number in laryngeal cancers as compared with nor-
mal laryngeal tissues [19]. However, the association of
mtDNA content with clinical outcomes of laryngeal can-
cer patients remains largely unknown.
In this study, using real-time quantitative PCR method,
we investigated mtDNA copy number in a large cohort of
laryngeal cancer tissues, and further explored the associ-




Informed consent was obtained from each patient accord-
ing to the protocols approved by the ethics committees of
the First Affiliated Hospital of Xi’an Jiaotong University
School of Medicine. A total of 204 paraffin-embedded la-
ryngeal cancer tissues and 40 paraffin-embedded non-
cancerous laryngeal tissues were randomly obtained at
the First Affiliated Hospital of Xi’an Jiaotong University
School of Medicine between January 2002 and September
2010. None of these patients had received radiotherapy or
chemotherapy before surgery. The histologic diagnosis of
tumors was made and agreed upon by at least two senior
pathologists at Department of Pathology of the Hospital
based on World Health Organization (WHO) criteria.
Relevant clinicopathological data were obtained from the
patients’ files or by interview with the patients or their rel-
atives, and the details were summarized in Table 1.
DNA preparation
Genomic DNA was extracted from paraffin-embedded tis-
sues as previously described [20]. Briefly, after a treatment
for 12 h at room temperature with xylene to remove paraf-
fin, the tissues were then subjected to digestion with 1%
sodium dodecyl sulfate (SDS) and proteinase K at 48°C for
48 h, with addition of several spiking aliquots of concen-
trated proteinase K to facilitate digestion. DNA wassubsequently isolated using a standard phenol-chloroform
extraction and ethanol precipitation protocol, and stored
at −80°C until use.
mtDNA copy number analysis
We measured the relative mtDNA copy number in a co-
hort of laryngeal cancers and normal laryngeal tissues by
real-time quantitative PCR method as described previ-
ously [21]. The specific primers and TaqMan probes for
MT-ND1 and β-actin genes used in this study were de-
signed using Primer Express 3.0 (Applied Biosystems,
Foster City, CA) and presented in Table 2. Using a PCR
protocol described previously [22], PCR amplification
Table 2 The primer and TaqMan probe sequences used in this study
Genes Forward primer sequence Probe sequence Reverse primer sequence Amplification
(5′→ 3′) (5′→ 3′) (5′→ 3′) Efficiency (%)
MT-ND1 CCCCTAAAACCCGCCACATC 6FAM-ACCCTCTACATCACCGCCCCGACC-TAMRA GTAGAAGAGCGATGGTGAGAGC 94.6
β-actin TCACCCACACTGTGCCCATCTACGA 6FAM-ATGCCCTCCCCCATGCCATCC-TAMRA TCGGTGAGGATCTTCATGAGGTA 95.2
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taining 16.6 mM ammonium sulfate, 67 mM Tris base,
2.5 mM MgCl2, 10 mM 2-mercaptoethanol, 0.1% DMSO,
0.2 mM each of dATP, dCTP, dGTP and dTTP, 600 nM
each of forward and reverse primers, 200 nM TaqMan
probe, 0.6 unit Platinum Taq polymerase and 2% Rox ref-
erence dye. Serial dilutions of normal leukocyte DNA were
used to establish standard curves. The internal reference
gene β-actin was run in parallel to standardize the input
DNA. Each sample was run in triplicate. The relative
mtDNA copy number of each sample was calculated as
described previously [23,24].Statistical analysis
The copy number of mtDNA between laryngeal cancer and
normal laryngeal tissues were compared by the Mann–
Whitney U test. Association of mtDNA copy number with
clinicopathological characteristics was univariately assessed
using the SPSS statistical package (version 11.5, Chicago,
IL). Multivariate models were then developed that adjusted
for the most important covariates, including gender, age,
smoking history, and TNM stage. The day of primary
tumor surgery to the day of death or last clinical follow-up
was used to determine the survival length. The Kaplan–
Meier method was used for survival analysis grouping with
mtDNA copy number. Differences between curves were
analyzed using the log-rank test. Multivariate Cox regres-
sion analysis was employed to evaluate the impact of vari-
able mtDNA copy number on survival of independently of
the number of lymph node metastasis, tumor invasion and
differentiation. All statistical analyses were performed using
the SPSS statistical package (version 11.5, Chicago, IL).
P values < 0.05 were considered significant.Results
Relative mtDNA copy number in laryngeal cancer
We investigated mtDNA copy number in a total of 204
laryngeal cancers and 40 normal laryngeal tissues using
real-time quantitative PCR assay. As shown in Figure 1A,
the relative mean mtDNA content was higher in laryn-
geal cancer patients (11.91 ± 4.35 copies) than control
subjects (4.72 ± 0.70 copies), which was consistent with a
previous study [16]. However, the difference did not
reach statistical significance (P =0.19). The median
values among laryngeal cancer patients and control
subjects were 4.92 copies (range =0.22-293.54 copies)and 4.92 copies (range =1.28-9.21 copies), respectively.
Moreover, a total of 30 pairs of laryngeal cancer tissues
and their corresponding normal tissues were compared
using Wilcoxon Signed Ranks test. The data showed that
there was not significant difference in relative mean
mtDNA copy number between cancer and normal tissues
(P =0.56) (Figure 1B).
We next evaluated whether mtDNA copy number differed
by selected clinicopathological characteristics. As shown in
Figure 2B, heavy-smoking patients had a lower mtDNA
copy number than those with mild or without smoking his-
tory (<10 pack- years: 17.39 copies; 10–25 pack-years: 10.23
copies; 25–40 pack-years: 11.51 copies; ≥40 pack-years: 5.78
copies, P =0.30). Also shown in Figure 2B, the tumors with
low mtDNA content were more aggressive as compared
with those with high mtDNA content (T1: 16.92 copies; T2:
11.92 copies; T3: 8.64 copies; T4: 3.96 copies; P =0.05). In
addition, the patients with late-stage tumors had a remark-
able lower mtDNA content than those with early-stage
tumors (stage I: 17.61 copies; stage II: 14.91 copies; stage III:
9.59 copies; stage IV: 4.97 copies; P =0.03), especially stage
IV. Moreover, we did not find significant associations of
mtDNA copy number with other clinicopathological fea-
tures, such as gender, age, differentiation, lymph node me-
tastasis and survival status (Figure 2B).
Association of variable mtDNA copy number with
clinicopathological characteristics of laryngeal cancer patients
To further investigate the relationship of mtDNA con-
tent with clinicopathological characteristics of laryngeal
cancer patients, we chosed two cutoff points, which are
the lower and upper limit (4.02 and 5.42 copies) of the
overall 95% confidence interval for all control subjects, re-
spectively. Laryngeal cancer patients were then categorized
into three groups by use of these two cutoff points, includ-
ing individuals with highest (>5.42 copies) (termed “high
mtDNA content” hereafter), medium (4.02-5.42 copies) and
lowest (<4.02 copies) (termed “low mtDNA content” here-
after) category of mtDNA content. Medium category of
mtDNA content (4.02-5.42 copies) was used as a reference.
As shown in Table 3, mtDNA copy number did not signifi-
cantly correlate with most of clinicopathological character-
istics. However, low mtDNA content was found to be
significantly associated with TNM stage (OR =1.53, 95%
CI =1.04-2.25; P =0.03), as compared with the reference.
Also shown in Table 3, high mtDNA content was signifi-
cantly negatively associated with smoking history (at least
Figure 2 Association of mtDNA copy number with clinicopathological variables in laryngeal cancer. Copy number of mtDNA was analyzed
using real-time quantitative PCR approach. Details are as described in Methods. (A) A frequency distribution of the number of cases by mtDNA copy
number, age, and pack-years. (B) The relationship of mtDNA copy number with various clinical features of laryngeal cancer patients. The circle represents
mtDNA copy number of each case of laryngeal cancers. Horizonal lines represent mean ± S.E. Sample means were compared using the Mann–Whitney U
test. F, female; M, male; Well, well/moderate differentiation; Poor, poor/undifferentiation; N, non-lymph node metastasis; Y, lymph node metastasis.
Figure 1 Copy number analysis of mtDNA in laryngeal cancer. (A) Copy number of mtDNA corresponding to each individual case of
laryngeal cancers and normal laryngeal tissues (circle). Real-time quantitative PCR assay was performed to analyze mtDNA copy number in a
cohort of laryngeal cancers and normal laryngeal tissues. Details are as described in Methods. (B) Copy number of mtDNA in 30 pairs of laryngeal
cancer tissues and their corresponding normal tissues by real-time quantitative PCR. Horizonal lines represent mean ± S.E. N, normal laryngeal
tissues; T, laryngeal cancer tissues.
Dang et al. Diagnostic Pathology 2014, 9:28 Page 4 of 9
http://www.diagnosticpathology.org/content/9/1/28
Table 3 Copy number variations of mtDNA in laryngeal
cancer — univariate associations with clinicopathological
characteristics
Characteristics Copy number <4.02 Copy number >5.42
OR* (95% CI) P OR* (95% CI) P
Male vs. Female 2.73 (0.37-20.28) 0.33 1.89 (0.30-11.86) 0.50
Age 1.00 (0.96-1.05) 0.92 1.01 (0.97-1.05) 0.78
Differentiation1 1.02 (0.25-4.10) 0.98 0.64 (0.17-3.01) 0.64
Tumor invasion2 1.43 (0.92-2.25) 0.11 0.94 (0.60-1.46) 0.77
TNM stage3 1.53 (1.04-2.25) 0.03 1.04 (0.71-1.51) 0.84
LNM4 2.31 (0.90-5.95) 0.08 1.50 (0.58-3.89) 0.41
Smoking history5 0.46 (0.16-1.34) 0.16 0.29 (0.10-0.84) 0.02
Survival status6 0.81 (0.36-1.84) 0.61 0.79 (0.35-1.77) 0.56
*OR: odds ratio with 95% confidence interval; 1Differentiation (well or
moderate; poor or undifferentiation); 2Tumor invasion (T1; T2; T3; T4); 3TNM
stage (I; II; III; IV); 4LNM (lymph node metastasis); 5Smoking history (at least 10
pack-years); 6Survival status (Alive vs. Dead); The cases with 4.02-5.42 mtDNA
copies were used as reference.
Table 5 Copy number variations of mtDNA in late-stage
laryngeal cancer— univariate associations with
clinicopathological characteristics
Characteristics Copy number <4.02 Copy number >5.42
OR* (95% CI) P OR* (95% CI) P
Male vs. Female 8.83 (0.74-105.58) 0.09 3.58 (0.46-28.17) 0.23
Age 0.99 (0.93-1.06) 0.76 0.97 (0.91-1.04) 0.37
Differentiation1 0.37 (0.08-1.81) 0.22 0.36 (0.07-1.84) 0.22
Tumor invasion2 1.05 (0.48-2.33) 0.90 0.78 (0.35-1.74) 0.54
LNM3 1.57 (0.48-5.12) 0.45 1.37 (0.41-4.56) 0.61
Smoking history4 0.78 (0.19-3.21) 0.73 0.49 (0.12-2.04) 0.33
Survival status5 0.64 (0.20-2.08) 0.45 1.05 (0.32-3.47) 0.94
*OR: odds ratio with 95% confidence interval; 1Differentiation (well or
moderate; poor or undifferentiation); 2Tumor invasion (T1; T2; T3; T4); 3LNM
(lymph node metastasis); 4Smoking history (at least 10 pack-years); 5Survival
status (Alive vs. Dead); The cases with 4.02-5.42 mtDNA copies were used
as reference.
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P =0.02). Although no statistical significance was noted,
there was a trend toward association of low mtDNA con-
tent with gender (OR =2.73, 95% CI =0.37-20.28; P =0.33)
and lymph node metastasis (OR =2.31, 95% CI =0.90-5.95;
P =0.08), respectively (Table 3).
Laryngeal cancer patients were further categorized into
two groups based on TNM stage, such as individuals with
early-stage (stages I and II) and late-stage (stages III and
IV) tumors. Given that most of the cases with early-stage
tumors are male (97.8%) and well differentiation (94.5%),
we did not investigate the associations of mtDNA content
with these two clinicopathological variables. As shown in
Table 4, high mtDNA content was significantly negatively
associated with smoking history in the patients with early-
stage tumors (OR =0.17, 95% CI =0.04-0.85, P =0.03).
However, we did not find the associations of variable
mtDNA content with the other characteristics in laryngeal
cancer patients. In addition, our data showed that variable
mtDNA content did not significantly correlate with any
clinicopathological variables in the patients with late-stage
tumors (Table 5). To assess the independent association ofTable 4 Copy number variations of mtDNA in early-stage
laryngeal cancer— univariate associations with
clinicopathological characteristics
Characteristics Copy number <4.02 Copy number >5.42
OR* (95% CI) P OR* (95% CI) P
Age 1.00 (0.94-1.06) 0.93 1.03 (0.98-1.09) 0.29
Tumor invasion1 1.25 (0.39-4.04) 0.71 0.48 (0.15-1.52) 0.21
Smoking history2 0.25 (0.05-1.31) 0.10 0.17 (0.04-0.85) 0.03
Survival status3 1.09 (0.34-3.54) 0.88 0.54 (0.17-1.69) 0.29
*OR: odds ratio with 95% confidence interval; 1Tumor invasion (T1; T2; T3; T4);
2Smoking history (at least 10 pack-years); 3Survival status (Alive vs. Dead); The
cases with 4.02-5.42 mtDNA copies were used as reference.mtDNA content with gender, age, smoking history and
TNM stage, we conducted multiple multivariable logistic
regressions. As shown in Table 6, similar to univariate
analysis, low mtDNA content remained significantly asso-
ciated with TNM stage (OR =1.62, 95% CI =1.09-2.41;
P =0.02). Moreover, high mtDNA content remained nega-
tively associated with smoking history (OR =0.27, 95%
CI =0.09-0.80; P =0.02) (Table 6).
Impact of variable mtDNA content on poor survival of
laryngeal cancer patients
Whether variable mtDNA content is associated with poor
survival of laryngeal cancer patients, as suggested by its as-
sociation with some of clinicopathological characteristics,
was then evaluated in this study. Similarly, medium cat-
egory of mtDNA content (4.02-5.42 copies) was used as a
reference. As shown in Table 7, variable mtDNA content
did not affect overall survival of laryngeal cancer patient.
Next, we used Kaplan-Meier survival curves to further de-
termine the effect of variable mtDNA content on the sur-
vival of laryngeal cancer patients. Similar to the findings in
Table 7, variable mtDNA content did not significantly
affect the survival of laryngeal cancer patients (39.4 monthsTable 6 Copy number variations in laryngeal cancer —
multivariable models assessing gender, age, smoking
history, and TNM stage
Characteristics Copy number <4.02 Copy number >5.42
OR* (95% CI) P OR* (95% CI) P
Gender 3.48 (0.46-26.59) 0.23 2.45 (0.37-16.42) 0.36
Age, years 1.00 (0.96-1.04) 0.96 1.00 (0.96-1.05) 0.87
Smoking history1 0.39 (0.13-1.17) 0.09 0.27 (0.09-0.80) 0.02
TNM stage2 1.62 (1.09-2.41) 0.02 1.12 (0.76-1.65) 0.57
*OR: odds ratio with 95% confidence interval; 1Smoking history (at least 10
pack-years); 2TNM stage (I; II; III; IV); The cases with 4.02-5.42 mtDNA copies
were used as reference.
Table 7 Prognostic value of clinicopathological factors and copy number variation of mtDNA in univariate and
multivariate Cox regression analysis (n =204)
Univariate analysis Multivariate analysis
Variable Hazard Ratio (95% CI) P Hazard Ratio (95% CI) P
Copy number
4.02 ~ 5.42 1.00 (reference) 1.00 (reference)
<4.02 1.00 (0.54–1.83) 0.99 1.78 (0.93–3.42) 0.09
>5.42 0.84 (0.53–1.34) 0.46 1.40 (0.84–2.35) 0.20
Lymph node metastasis
No 1.00 (reference) 1.00 (reference)
Yes 2.70 (1.71–4.25) <0.001 2.43 (1.46–4.05) 0.001
Tumor invasion
T1 1.00 (reference) 1.00 (reference)
T2 1.98 (1.15–3.43) 0.015 1.71 (0.95–3.06) 0.07
T3 2.32 (1.29–4.18) 0.005 2.24 (1.22–4.14) 0.01
T4 5.46 (2.28–13.11) <0.001 5.42 (2.08–14.13) 0.001
Differentiation
Well/moderate 1.00 (reference) 1.00 (reference)
Poor/undifferentiation 2.78 (1.10–7.07) 0.03 2.33 (0.88–6.15) 0.09
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mtDNA content vs. 44.1 months for high mtDNA content
on average, P =0.73) when the patients were divided into
low (≤4.02), median (4.02-5.42), and high (>5.42) mtDNA
content groups (Figure 3A). Cox multivariate repression
showed that low or high mtDNA content (the former:
HR =1.78, 95% CI =0.93-3.42, P =0.09; the latter:
HR =1.40, 95% CI =0.84-2.35, P =0.20) is not a predictor
of poor survival for laryngeal cancer patients as an inde-
pendently variable with respect to lymph node metastasis,
tumor invasion and differentiation. The data were strati-
fied further based on the TNM tumor stage, because it is
an independent risk factor for laryngeal cancer patients.
Also shown in Figure 3A, although the difference did not
reach statistically significant, low mtDNA content was as-
sociated with worse survival in the patients with early-
stage tumors as compared with medium and high mtDNA
content (47.1 months vs. 55.6 months and 57.9 months on
average, P =0.20). However, variable mtDNA content did
not affect the survival of the patients with late-stage tu-
mors (35.1 months for low mtDNA content vs. 26.8 months
for medium mtDNA content vs. 30.9 months for high
mtDNA content on average, P =0.28). To further deter-
mine the effect of variable mtDNA content on poor sur-
vival, the patients were divided into low (≤4.72) and high
(>4.72) copy number groups by using relative mean
mtDNA copy number (4.72 copies) of all control subjects
as cutoff point. As shown in Figure 3B, the patients with
low mtDNA content had significantly shorter survival time
than those with high mtDNA content in the early-stage tu-
mors (47.9 months vs. 58.2 months on average, P =0.03).Similarly, high mtDNA content was not associated with
poor survival of the patients with late-stage tumors
(Figure 3B).
Discussion
Given the essential involvement of mitovhondria in cellu-
lar bioenergetic and in many important physiological pro-
cesses, including metabolism, signaling, apoptosis, cell
cycle, and differentiation, it is not surprising that mito-
chondria dysfunction can contribute to the development
of various human disease, inculding cancers [25,26]. Un-
like nuclear DNA, mtDNA is present at a consistently
high level in normal cells [27], and the mitochondrial gen-
ome lacks introns and protective histones. As a con-
sequence, the mutation rate of mtDNA is substantially
greater than that of nuclear genomic DNA [26,28]. It has
been well documented that excess reactive oxygen species
(ROS) acts not only mutagens and initiators of oxidative
stress, but are also significant inter- and intra-cellular sig-
naling molecules, contribute to a number of nuclear and
mitochondrial changes in gene expression [29,30]. More-
over, mitochondrial has been reported to be highly suscep-
tible to ROS [31]. ROS is thus often considered as an
important determinant of cancer risk.
Mitochondrial aberrants, including mtDNA somatic mu-
tations and copy number variations, have been frequently
reported in various human cancers [13,21,24,32-35], in-
cluding laryngeal cancer [19]. However, the prognostic
value of copy number variations of mtDNA in laryngeal
cancer patients remains to be explored. In this study, we
investigated relative mtDNA copy number in a cohort of
Figure 3 The effect of variable mtDNA content on poor survival of laryngeal cancer patients. The lower and upper limit (4.02 and 5.42
copies) of the overall 95% confidence interval for all control subjects (A) and the relative mean mtDNA copy number (4.72 copies) of all control
subjects (B) were set as the cutoff points, respectively. Kaplan-Meier analysis of survival was then performed according to copy number variations
of mtDNA in a large cohort of laryngeal cancers. The results showed that both low and high mtDNA content were not associated with overall sur-
vival of the patients. However, when the data were stratified further based on the TNM tumor stage, low mtDNA content was strongly associated
with worse survival in the patients who had early-stage tumors, but not in those with late-stage tumors. H, high mtDNA content; M, medium
mtDNA content (or reference); L, low mtDNA content.
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jects) by using real-time quantitative PCR method. Our
data showed that relative mean mtDNA content was
higher in laryngeal cancer patients than control subjects.
In line with this finding, a previous study has reported the
increased mtDNA copy number in laryngeal cancer tissues
as compared with paracancerous normal tissues, and dem-
onstrated that mtDNA copy number in the cases which
carried D-loop mutations was significantly higher than that
of the negative cases [19]. These observatiosns suggest that
the increase in mtDNA copy number, together with a high
frequence of mtDNA mutations or polymorphisms in D-
loop region, may play a key role in larynx carcinogenesis.
Moreover, we did not find the associations of mtDNA con-
tent with gender, age, differentiation, and survival status.
However, our data demonstrated that mtDNA copy num-
ber was significantly negatively associated with cigarette
smoking, as supported by a previous study that cigarette
smoking could modulate the mtDNA content in a nega-
tive manner in the lung tissues of the smokers [36]. We
also found that low copy number of mtDNA was signifi-
cantly positively associated with tumor invasion depth. In
addition, our data showed that mtDNA copy number was
closely associated with TNM stage. The patients with late-stage tumors had a significant lower mtDNA copy number
than those with early-stage tumors. These findings suggest
that variable mtDNA content, particularly low mtDNA
content, may contribute to poor prognosis of laryngeal
cancer patients.
To further explore the association of mtDNA content
with clinical outcomes of laryngeal cancer patients, we
categorized the patients into three groups by using two
cutoff points (the lower and upper limit of 95% confi-
dence interval for all control subjects), including low
mtDNA content (<4.02 copies), medium mtDNA con-
tent or reference (4.02-5.42 copies) and high mtDNA
content (>5.42 copies). Our data showed that mtDNA
content was significantly negatively associated with
TNM stage in laryngeal cancer patients, as supported by
a previous study that positive correlation was found with
decrease in mtDNA content with the increase in tumor
stages in oral cancer [37]. Moreover, our data also
showed that low mtDNA content was closely associated
with an increased risk of lymph node metastasis for la-
ryngeal cancer patients as compared to reference. When
the patients were further categorized into early-stage
and late-stage groups based on TNM stage, a signifi-
cantly negative relationship between mtDNA content
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http://www.diagnosticpathology.org/content/9/1/28and smoking history was only found in the patient with
early-stage tumors, but not in those with late-stage tu-
mors. These observations suggest that copy number var-
iations of mtDNA may be invloved in laryngeal cancer
progression. Next, we investigated the effect of variable
mtDNA content on poor survival of laryngeal cancer pa-
tients. The data showed that both low and high mtDNA
content were not associated with overall survival of can-
cer patients. However, further analysis revealed that low
mtDNA content was closely associated with poor sur-
vival only in the patients with early-stage tumors, but
not in those with late-stage tumors. These data implicate
that low mtDNA content can predict worse survival in
the early-stage laryngeal cancer patients, as supported by
a previous study that low mtDNA copy number may re-
sult in a stronger tolerance to hypoxia, and make tumor
cells reduce the dependence of mitochondrial oxidative
phosphorylation and get the energy for tumor progres-
sion mainly from anaerobic metabolism, further contrib-
ute to tumor cell invasion and survival under hypoxic
conditions [38].
In conclusion, we investigated relative mtDNA content
in a large cohort of laryngeal cancers, and demonstrated
that mtDNA content was negatively associated with
cigarette smoking, tumor invasion and TNM stage. In
addition, low mtDNA content predicts worse survival
for the patients with early-stage tumors. Therefore, vari-
able mtDNA content may be used as a valuable bio-
marker to evaluate clinical outcomes of early-stage
laryngeal cancer patients.
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